Skip to content
Catalyst

PapersPMID:23935377

Effects of Phyllanthus emblica extract on endothelial dysfunction and biomarkers of oxidative stress in patients with type 2 diabetes mellitus: a randomized, double-blind, controlled study.

Diabetes, metabolic syndrome and obesity2013The record ↗

findings
5
compound
1
endpoints
5
PMID:23935377
  1. Finding, moderate evidencelowersC-reactive protein concentration
  2. Finding, moderate evidencelowersTotal cholesterol (TC)
  3. Finding, moderate evidencelowersLDL cholesterol
  4. Finding, moderate evidencelowersTriglycerides
  5. Finding, moderate evidenceraisesHDL cholesterol
Study, every finding
RCT · 3 months
Dose studied, every finding
250 mg or 500 mg twice daily for 12 weeks (two dose arms)
Population, every finding
Adults aged 30 to 68 with type 2 diabetes (fasting glucose 110-126 mg/dL, HbA1c 7-9%) and endothelial dysfunction, all on stable metformin 1,500-3,000 mg in every arm; 20 per arm; both amla dose arms reported together; an atorvastatin arm also ran against the same placebo

What moved

How to read these marks →
  • Decreases C-reactive protein concentration

    moderate

    “The effect of the trial medications on biomarkers is shown in Table 3, indicating that P. emblica 250 mg, P. emblica 500 mg, and atorvastatin significantly decreased high sensitivity C-reactive protein levels compared with baseline and placebo.”
    Interests
    Industry funded
  • “Treatment with P. emblica 250 mg, P. emblica 500 mg, and atorvastatin siginificantly reduced the levels of total cholesterol, low-density lipoprotein cholesterol, and triglycerides, and increased high-density lipoprotein cholesterol levels compared with baseline and placebo.”

Study record

Design
randomised controlled trial
Species
human
Population
Men and women aged 30-68 years with type 2 diabetes mellitus on stable metformin, Hyderabad, India
Participants
80
Comparator
placebo
Duration
84 days
Endpoints measured
31